Edmond de Rothschild Investment Partners has co-led the Series B financing round of Complix with GIMV. Complix, formed in 2008, was founded in Hasselt, Belgium. The funds will be invested in developing a first set of therapeutic Alphabodies(TM) to treat cancer and autoimmune indications and to further develop and validate the company’s unique Alphabody platform.
Edmond de Rothschild Investment Partners announces the second investment of BioDiscovery 4, its fourth fund dedicated to Life Sciences, through its participation in the Series B financing round of Complix, which it co-leads with GIMV.
Complix, formed in 2008, was founded in Hasselt, Belgium. Edmond de Rothschild Investment Partners led alongside GIMV the Series B round financing of €12 million which will be invested in developing a first set of therapeutic Alphabodies(TM) to treat cancer and autoimmune indications and to further develop and validate the Company’s unique Alphabody platform.
Complix is developing Alphabodies, a transformative biotherapeutic platform with the ability to modulate the intracellular protein-to-protein interactions (PPIs), which play a key role in the initiation and progression of many important diseases. As such, these Alphabodies have the capacity to address a vast number of disease targets that are currently considered “undruggable” by the two main classes of therapeutic drugs, small chemical drugs and therapeutic proteins, and represent a major medical and commercial opportunity for Complix and its partners.
Gilles Nobecourt, Partner at Edmond de Rothschild Investment Partners, who will join the Board Director at Complix, commented: “We were attracted by Alphabodies’ unique ability to modulate intracellular protein-protein interactions which offers an unprecedented opportunity to create a new class of proprietary and truly differentiated products. We were impressed by the team at Complix, which has created this new scaffold and demonstrated in-vitro its potential to address intractable intra cellular targets. Based on this initial success we believe there is a strong basis for building a successful company”.
Mark Vaeck, Co-Founder and CEO of Complix added: “We look forward to working with our new investors Edmond de Rothschild Investment Partners and GIMV to ensure the expeditious implementation of our ambitious plans and vision. We are confident that our Alphabody platform can deliver the next generation drugs that the pharmaceutical industry is eagerly looking for to drive its growth and tackle a broad range of diseases where treatment options are limited or non-existent.”
About Edmond de Rothschild Investment Partners
Paris-based Edmond de Rothschild Investment Partners is dedicated to minority investments into privately-owned companies. It currently has close to €1 billion under management which is being invested primarily as life sciences venture capital and growth capital.
Its Life Sciences Team of eight professionals brings together over 60 years of experience in the Life Science industry and more than 100 years of private equity and venture capital experience. The team has €355 million under management through its Biodiscovery franchise.
BioDiscovery Funds, including BioDiscovery 4, are venture capital funds registered via the fast-track procedure. These funds are not authorized by the Autorité des Marchés Financiers and may adopt special investment rules. BioDiscovery 4, a Capital Venture Funds registered via the fast-track procedure, invests mainly in private companies, which involves specific risks such as a risk of capital loss, a discretionary management risk and a liquidity risk.
Edmond de Rothschild Investment Partners is the private equity affiliate of the Edmond de Rothschild Group, which is specialised in asset management and private banking (EUR 130bn under management, 2,900 employees and 30 offices throughout the world). Founded in 1953, the Group has been chaired since 1997 by Baron Benjamin de Rothschild.
Complix is a biopharmaceutical company developing a pipeline of transformative protein therapeutics, called Alphabodies(TM), mainly focused on oncology and autoimmune diseases.
Alphabodies are a revolutionary class of protein therapeutics that have the potential to address a wide range of disease targets, in particular intracellular targets that are considered undruggable by current drug formats, such as antibodies or small chemicals. Complix` current R&D efforts are mainly focused on the development of Cell-Penetrating Alphabodies (CPABs) that have the unique capacity to enter tumor cells effectively and selectively modulate intracellular protein-to-protein interactions (PPIs) which play a key role in the initiation and progression of cancer.
Complix has established a strong intellectual property position protecting the Alphabody(TM) platform and its emerging product portfolio through the filing of multiple broad patent applications. Alphabody-based therapeutics are independent of antibody-based patent claims and offer a unique freedom-to-operate position.
Since its founding in 2008 Complix has raised a total of €26 million in funding (approximately US$ 34 million), including a €12 million B round in June 2013 and a €7 million Series A equity round in 2010.
Complix is headquartered in Hasselt (Belgium) in the Life Sciences incubator BioVille, and has research facilities in Ghent (Belgium) and Luxembourg. The Company has a fully owned subsidiary in Luxembourg and has established research alliances with CRP-Santé (Luxembourg) and VIB (Belgium).
Edmond de Rothschild Investment Partners
Tel: +33 1 40 17 27 69
Dr. Mark Vaeck, CEO
Tel: +32 9 261 69 40